FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 643 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer MOST POPULAR The Winter Solstice December 16, 2020 2023 ASCO Annual Meeting Research Round Up: Progress in Treating Breast... July 27, 2023 FDA Grants Accelerated Approval to Daratumumab Plus Hyaluronidase for Newly Diagnosed... January 22, 2021 Workout Wednesdays – Leg Exercises Part 3 June 24, 2020 Load more HOT NEWS 20.° Aniversario de Cancer.Net: Celebramos Nuestra Misión de Brindar Información Confiable... Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer The Childhood Cancer Data Initiative: Why Data Sharing Is Essential to... What Are Drug Shortages and How Can They Impact Care for...
